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12p70 secretion, naive CD4 T cell expansion, Th1 and Tc1 cells
differentiation) in the context of RIC allo-SCT. The ﬁne functions
of immune effectors would tend to be more evident in such less
toxic regimens, offering new opportunities for a better understand-
ing of aGVHD pathophysiology and therapy.
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RAPAMYCIN ADDED TO HUMAN CD25 CELL CULTURES ACTIVATED
THROUGH CD3/CD28 ENRICHES FOR CD4CD25CD27Foxp3
REGULATORY T CELLS
Keever-Taylor, C.A., Browning, M.B., Johnson, B.D., Truitt, R.L.,
Behn, B.A. Medical College of Wisconsin, Milwaukee, WI.
CD4 T cells that constitutively express high levels of CD25
inhibit T-cell responses in a dose-dependent manner. Methods to
isolate and expand CD4CD25 regulatory T-cells (Tregs) have
been developed to allow for potential clinical use in regulating
undesired T cell-mediated responses such as autoimmune disease
or GVHD. We have enriched for Tregs by CD25 positive selec-
tion followed by culture in ex vivo 15-5% HS and autologous
feeder cells. Activation is through a single addition of CD3/CD28
Ab-linked beads (4:1 bead:cell) and IL-2 (100 U/mL added d 3).
Cultures with potent suppressor activity expanded on average 450
fold in 14 d when maintained at 5  105/mL in medium  IL-2.
However, by 21 d suppressor activity greatly diminished and the %
of CD25-bright cells decreased, indicating activated non-Treg
cells were dominating the cultures. To increase the purity of Tregs
we explored the use of rapamycin, a T cell immunosuppressive
agent recently shown to selectively spare murine Tregs. Rapamy-
cin (20-0.01 ng/mL) added to CD25-enriched cells signiﬁcantly
inhibited cell expansion at doses 1 ng/mL that was inversely
correlated with enhanced suppressor activity at days 10 and 21.
Cultures without rapamycin expanded on average 17,000 fold by
day 21 vs 350 fold with 1 ng/mL rapamycin. By 21 d cells from
untreated cultures suppressed allo-proliferation by only 28% at a
1:1 suppressor:responder ratio compared to 63  20% by cells
grown in 1 ng/mL rapamycin (P  .007). The %
CD4CD25bright cells at 10 d and 21 d was higher in rapamycin-
containing cultures than untreated cultures, P  .003. Intracellular
FACS staining for the transcription factor Foxp3, a marker for
Tregs, showed signiﬁcantly higher expression on CD4 cells from
10 d rapamycin containing cultures with 23  6% Foxp3CD4
cells vs 5  3% in cultures without rapamycin (P  .03, n  4).
Foxp3 was predominately expressed on CD4CD25-bright cells
that also co-expressed CD27-bright. By day 21 cultures grown in
rapamycin contained 1000 to 5000 fold more CD4Foxp3 cells
than 10 d cultures without rapamycin. Only 0.7% of CD4 cells
from CD4CD25-neg cells cultured with rapamycin expressed
Foxp3. Optimal Foxp3 expression required continued presence of
rapamycin in culture and addition at culture initiation was superior
to addition at day 3. In summary, addition of rapamycin at doses
from 1-20 ng/mL to CD25-enriched cell cultures increased the
purity of cells with the phenotype and function of Tregs.
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PROSPECTIVE EVALUATION OF A GvHD-SPECIFIC PROTEOMICS PAT-
TERN AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
Weissinger, E.M.1, Hillmann, M.2, Dammann, E.1, Kolb, H.-J.3,
Holler, E.4, Mischak, H.2, Ganser, A.1, Hertenstein, B.5 1Hannover
Medical School, Hannover, Germany; 2Mosaiques Diagnostics GmbH,
Hannover, Germany; 3Ludwig-Maximilians-University, Munich, Ger-
many; 4University of Regensburg, Regensburg, Germany; 5Klinikum
Bremen Mitte gGmbH, Bremen, Germany.
We have recently published a polypeptide pattern speciﬁc for the
early diagnosis of acute graft versus host disease (aGvHD), based
on the application of capillary electrophoresis (CE) and mass spec-
trometry (MS). Here we report the application of aGvHD-speciﬁc
patterns to prospectively collected samples from 86 patients (45
AML, 14 ALL, 8 MM, 5 CLL, 5 SAA, 3 MDS, 3CML, 3 NHL).
Fifty-three patients were transplanted from matched unrelated
donors (MUD), 29 received stem cells from matched related do-
nors (MRD), 3 from haplo-identical donors and 1 was transplanted
from a syngeneic sibling. In the majority of the patients the GvHD
prophylaxis was methotrexate or mycophenolate and cyclosporin
A. Urine samples were collected on ice prior to conditioning,
weekly until discharge from the ward and monthly thereafter.
Immediate freezing of the samples avoids degradation of the pro-
teins/peptides. After thawing and removal of confounding sub-
stances like salts and of all molecules larger than 30 kDa, the
samples were loaded onto the CE, separated according to their
charge and, after ionization, directly analyzed in an electrospray-
ionization time-of-ﬂight (ESI-TOF)-MS. Between 500 and 2500
peptides and proteins were detected in individual samples. All data
generated are stored in a Microsoft MS database. The polypeptide
patterns speciﬁc for the early detection of acute GvHD were
applied to the data from the prospectively and blinded collected
samples. The outcome of these analyses was compared to the
clinical diagnosis of aGvHD, sepsis and CMV-reactivation. In 362
samples screened, 112 scored positive with the GvHD pattern.
Twenty-eight of those were false positive, mainly at the time of
conditioning, but only 3 were scored false negative. Thus the
sensitivity of the aGvHD pattern is about 96% with a 75% positive
prediction value, the speciﬁcity is about 89% with a negative
prediction value of 98%. Thus the application of the aGvHD
pattern for early recognition of acute GvHD is very useful for
predicting the development of aGvHD. Seven patients in the
prospective cohort have developed cGvHD so far and samples
were also scored with the aGvHD pattern. First results show that
in the majority of the patients the polypeptides excreted do not
correspond to those forming the aGvHD pattern. Taken together
our results demonstrate that the proteome analysis of body ﬂuids





UMBILICAL CORD BLOOD TRANSPLANTATION IN PEDIATRIC PA-
TIENTS: RESULTS OF THE PROSPECTIVE, MULTI-INSTITUTIONAL CORD
BLOOD TRANSPLANTATION STUDY (COBLT)
Kernan, N.A.1, Carter, S.L.2, Wagner, J.E.3, Baxter-Lowe, L.4,
Wall, D.5, Kapoor, N.6, Guinan, E.7, Wagner, E.8, Geller, N.8,
Kurtzberg, J.9 1Memorial Sloan-Kettering Cancer Center, New York,
NY; 2The EMMES Corporation, Rockville, MD; 3University of Min-
nesota, Minneapolis, MN; 4University of California, San Francisco, CA;
5Texas Transplant Institute, San Antonio, TX; 6Children’s Hospital of
Los Angeles, Los Angeles, CA; 7Dana Farber Cancer Institute, Boston,
MA; 8The National Heart, Lung and Blood Institute, Bethesda, MD;
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In 1996, NHLBI sponsored COBLT, a prospective study that
established 3 cord blood banks that banked8000 CBUs, and funded
28 transplant centers to participate in a clinical trial with the primary
endpoint of 180-day post-transplant overall survival (OS). The trial
enrolled 316 pediatric pts with median age 4.6 years (range 0.1-17.9),
61% M, 37% minorities, 44% CMV and 71% with a malignant
(malign) disease, who received a single CBU. CBUs had to be at least
4 of 6 HLA match (intermediate resolution A and B and high reso-
lution [HR] DRB1) and provide a total nucleated cell dose (TNC)
1.0  107/kg. Approximately 50% of Caucasian and Hispanic pts
received a CBU matched at HLA 5-6/6, but only 15% of African-
Americans and 36% of Asians were matched at HLA 5-6/6. HRHLA
types were retrospectively determined for HLA -A, -B, -DRB1 (292
pairs) and -C and -DQB1 (270 pairs). Only 30% of pairs were HR
HLA matched at 8-10 alleles. The median pre-cryopreservation
TNC and CD34 cell dose were 6.8  107/kg (range 1.5-50.4) and
2.3 105/kg (range 0.1-20.1), respectively. The cumulative incidence
(CINC) of neutrophil recovery (	500, day 42) and of platelet engraft-
ment (	50000, day 180) was 81% and 54%, respectively. By day
100, the CINC of grades II-IV aGVHD was 40%. The CINC of
cGVHD was 21% at 2 yrs. The probability of OS at 180 days
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post-transplant was 69% (95%CI 64%, 74%). For pts with malignant
disease, disease-free survival at 1 year was 50% (95% CI 43%, 56%).
Based on Cox proportional hazards models, the success of transplan-
tation was predominantly dependent on pt characteristics: pts with
non-malign disease, CMV seronegativity, and males had improved
outcomes. CD34 dose was associated with improved neutrophil and
platelet engraftment. In multivariate analyses, TNC (95% pts had
2.5  107/kg), HLA match (4/6 vs 5 or 6/6 types at transplant) or
HR HLA match (8/10 vs 8/10) were not signiﬁcantly associated
with any of the end points. In conclusion, HLA 4-6 of 6 matched
CBUs with 2.5  107/kg TNC provide excellent transplant results
for pediatric patients with malign (OS 57% [95% CI 50%, 63%] at 1
year) and non-malign (OS 71% [95% CI 61%, 80%] at 1 year)
diseases.
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UNRELATED CORD BLOOD TRANSPLANTATION AFTER MYELOABLA-
TIVE CONDITIONING IN ADULT PATIENTS WITH ACUTE LEUKEMIA
Ooi, J., Takahashi, S., Tomonari, A., Asano, S., Tojo, A. Department
of Hematology and Oncology, Institute of Medical Science, University of
Tokyo, Tokyo, Japan.
Although allogeneic stem cell transplantation from a human
leukocyte antigen (HLA)-identical related donor offers a potential
cure for patients with acute leukemia, a suitably matched related
donor is unavailable for approximately two-thirds of patients. Re-
cently, umbilical cord blood from unrelated donors has been used
as an alternative stem cell source for adult patients with hemato-
logical malignancies. Here, we updated the results of unrelated
cord blood transplantation (CBT) after myeloablative conditioning
for 69 adult patients with acute leukemia. Between August 1998
and April 2005, 69 adult patients with acute leukemia were treated
with unrelated CBT at The Institute of Medical Science, Univer-
sity of Tokyo. Diagnoses at transplantation included de novo AML
(n  38), ALL (n  16), and MDS-related secondary AML (n 
15). All patients received four fractionated 12 Gy total body irra-
diation and chemotherapy as myeloablative conditioning. 66 pa-
tients received standard cyclosporine (CyA) and methotrexate, and
3 patients received CyA only as a graft-versus-host disease
(GVHD) prophylaxis. Among the patients the median age was 41
years (range, 18-55 years), the median weight was 55 kg (range,
36-76 kg) and the median number of cryopreserved nucleated cells
was 2.50  107/kg (range, 1.16-5.29  107/kg). 65 patients had
myeloid reconstitution and the median time to more than 0.5 
109/L absolute neutrophil count was 21 days. A self-sustained
platelet count more than 50 109/L was achieved in 59 patients at
a median time of 39 days. Acute GVHD above grade II occurred in
39 of 65 evaluable patients and chronic GVHD occurred in 37 of
47 evaluable patients. Among 37 chronic GVHD patients, 12
patients were extensive type. 46 patients are alive and free of
disease at between 126 and 2562 days after transplantation. With a
median follow-up of 1259 days, the probability of disease-free
survival at 3 years was 69.0%. These results suggest that adult acute
leukemia patients without suitable related or unrelated bone mar-
row donors should be considered as candidates for CBT.
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IMPACT OF DONOR KIR GENOTYPE AND RECIPIENT HLA LIGAND
INCOMPATIBILITY ON RELAPSE RELATED MORTALITY AND ACUTE
GRAFT VERSUS HOST DISEASE IN HIGH-RISK PATIENTS UNDERGOING
HAPLOIDENTICAL NON-MYELOABLATIVE PERIPHERAL BLOOD STEM
CELL TRANSPLANTS: DIFFERENCES BETWEEN LYMPHOID AND MY-
ELOID MALIGNANCIES
Prasad, V.K.1, Chen, D.-F.2, Reinsmoen, N.L.2, Broadwater, G.3,
Chao, N.J.4, Rizzieri, D.A.4 1Pediatric Blood and Marrow Transplan-
tation Program, Duke University Medical Center (DUMC), Durham,
NC; 2Clinical Transplantation Immunology Laboratory, Department of
Pathology, DUMC, Durham, NC; 3Cancer Center Biostatistics,
DUMC, Durham, NC; 4Division of Cellular Therapy, Department of
Medicine, DUMC, Durham, NC.
Failure to recognize the appropriate HLA class I ligands on the
target cell triggers the inhibitory killer Ig-like receptors (KIR) to
initiate cytotoxicity and may contribute to graft-vs.-leukemia
(GVL) effect. Past studies have shown GVL advantage of the
absence (incompatibility) of recipient HLA ligands to donor KIR
genes in select patients (pts) undergoing myeloablative transplan-
tation. Here we examine if similar advantage is seen in non-
myeloablative transplant (NMT). The KIR-HLA ligand combina-
tions studied were: KIR2DL1-Cw4 (Asn77Lys80); KIR2DL2/3-
Cw3 (Ser77Asn80); KIR3DL1-Bw4; and KIR3DL2-A3/A11. The
KIR typing was performed by rSSOP and HLA-C allele typing by
SBT. Twenty-two lymphoid malignancy (LM) pts with ALL, HD,
or NHL and 20 myeloid malignancy (MM) pts with AML or MDS
were studied. The median age of LM and MM were both 45 years.
All had relapsed/refractory disease, and/or co-morbidities preclud-
ing ablative transplantation. Peripheral blood hematopoietic stem
cell graft from haploidentical family donors with alemtuzumab (20
mg  5), ﬂudarabine (30 mg/m2  4), and cyclophosphamide (500
mg/m2 4) regimen and mycophenolate cyclosporine in vitro
alemtuzumab prophylaxis was used. Most donors were 3-4/6 HLA
matched (75% in MM and 82% in LM). Each pair was evaluated
for the donor KIR genotype and lack of corresponding class I
ligands. Kaplan-Meier curves were compared using log-rank test.
The impact of NK cell cytotoxicity was assessed by relapse related
mortality (RRM). RRM in MM group was appreciably lower if
there was KIR/HLA-C ligand incompatibility (P .059). One year
probability of RRM is 14% (95% conﬁdence: 0-37%) in the in-
compatible group compared to 71% (95% conﬁdence: 28-89%) in
the compatible group (P  .059). In addition, RRM is lower
though not reaching statistical signiﬁcance (P  .070) if the in-
compatibility existed for 2 or 3 KIR/HLA ligand combinations
(17%; 95% conﬁdence: 0-42%) in comparison to no or 1 combi-
nation (66%; 95% conﬁdence: 25-85%). There were no differ-
ences in RRM in LM group (P  .784 for HLA-C; P  .16 for
Bw4; 0.752 for A3/11) with regard to KIR/HLA ligand matching.
KIR-HLA ligand incompatibility did not increase the probability
of grade 2-4 AGVHD in the MM group (P .247 for HLA-C; P
.467 for Bw4; 0.357 for A3/11). These results suggest that KIR/
HLA ligand incompatibility contributes to GVL effect without an




ADOPTIVE IMMUNOTHERAPY WITH ALLODEPLETED DONOR T-CELLS
IMPROVES IMMUNE RECONSTITUTION AFTER HAPLOIDENTICAL STEM
CELL TRANSPLANT
Amrolia, P.J.1, Muccioli-Casadei, G.2, Huls, H.M.3, Durett, A.3,
Weiss, H.3, Rooney, C.M.3, Kuehnle, I.3, Ghetie, V.4, Schindler, J.4,
Rao, K.1, Heslop, H.E.3, Veys, P.A.1, Vitetta, E.4, Brenner, M.K.3
1Department of Bone Marrow Transplantation, Great Ormond St.
Childrens Hospital, London, United Kingdom; 2CEINGE Biotechnologie
Avanzale and Dipartimento di Biochimica e Biotecnologie Medicine,
University Federico II di Napoli, Naples, Italy; 3Center for Cell and Gene
Therapy, Baylor College of Medicine, Houston, TX; 4Cancer Immuno-
biology Center, University of Texas Southwestern Medical School, Dallas,
TX.
One of the major barriers to the broader use of haploidentical
stem cell transplantation (SCT) is the high mortality from viral
infections due to poor immune reconstitution. One approach to
safely overcome this problem is to infuse donor T-cells from which
alloreactive lymphocytes have been selectively depleted, but the
immunological beneﬁt of this approach is unknown. We have
previously demonstrated that an anti-CD25 immunotoxin effec-
tively depletes alloreactive donor lymphocytes from co-cultures of
donor mononuclear cells and host lymphoblastoid cell lines with
preservation of in vitro anti-viral responses. In the current study we
have compared immune reconstitution after allodepleted donor
T-cells were infused at 2 dose levels into recipients of haploiden-
tical SCT. Patients were scheduled to receive 3 doses of allode-
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